Medicine
Zemplar 10 mcg/2 mL injection
Zemplar 10 mcg/2 mL injection is a prescription medicine containing Paricalcitol for intravenous use, marketed by AbbVie, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at 25°C (77°F). Excursions permitted between 15° to 30°C (59° to 86°F)…
Key facts
- Active ingredient (INN)
- Paricalcitol
- Brand
- Zemplar
- Strength
- 10 mcg/2 mL
- Dosage form
- Injection
- Route
- Intravenous
- Packs
- 25 vials of 2 mL
- Marketing authorisation holder
- AbbVie
- Manufacturer
- AbbVie
- Origin register
- US FDA, United States
- Storage
- Store at 25°C (77°F). Excursions permitted between 15° to 30°C (59° to 86°F). The contents of the multiple-dose vial remain stable up to seven days after initial use when stored at controlled room temperature.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- H05BX02 Paricalcitol
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 17 April 1998
- Identifiers
- RxCUI 200321, 213298, 352076 +3DailyMed set ID 7259652f-81bc-4ad1-bba5-d01f9fac1b80NDC 0074-1658Application NDA020819
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 25 vial, multi-dose in 1 tray / 2 mL in 1 vial, multi-dose | 0074-1658-05 | AbbVie | 17 April 1998 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 17 April 1998 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Paricalcitol 10 mcg/2 mL injection.
Other strengths and forms of Paricalcitol
Clinical summary
Paricalcitol is a vitamin D2 analog indicated for the prevention and treatment of secondary hyperparathyroidism in patients 5 years of age and older with chronic kidney disease (CKD) on dialysis. MedsAcross supplies Paricalcitol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about ParicalcitolFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Zemplar prescribing information (AbbVie) · U.S. National Library of Medicine, DailyMed
Need Zemplar 10 mcg/2 mL injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.